5 Biotech Stocks To Buy According To Chinese Billionaire Lei Zhang

Page 5 of 5

1. BeiGene, Ltd. (NASDAQ:BGNE)

Hillhouse Capital Management’s Stake Value: $1,986,430,000

Percentage of Hillhouse Capital Management’s 13F Portfolio: 25.98%

Number of Hedge Fund Holders: 16

BeiGene, Ltd. (NASDAQ:BGNE) is the largest holding in billionaire Lei Zhang’s Q3 portfolio. Zhang’s Hillhouse Capital Management owns 5.4 million shares of BeiGene, Ltd. (NASDAQ:BGNE), a biotech company specializing in the development of drugs for cancer, worth $1.98 billion, representing 25.98% of the firm’s total investments. 

On October 12, Bernstein analyst Liang Rebecca initiated coverage of BeiGene, Ltd. (NASDAQ:BGNE) with an Outperform rating and a $431 price target. The analyst covered the China biotech and pharma sector “with a positive stance based on the global opportunity.”

Billionaire Ray Dalio’s Bridgewater Associates is one of the largest BeiGene, Ltd. (NASDAQ:BGNE) stakeholders as of Q3 2021, with the hedge fund elevating its stake in the company by 105%, holding 175,923 shares worth $63.8 million. Overall, 16 funds were long BeiGene, Ltd. (NASDAQ:BGNE) in the third quarter. 

You can also take a look at 10 Healthcare Dividend Stocks with Over 3% Yield and Jim Cramer’s Most Favorite Tech Stocks to Buy Now

Page 5 of 5